ARTICLE | Company News
Antex Biologics other research news
October 14, 1996 7:00 AM UTC
The NIH awared Antex a $600,000 Phase II SBIR grant to develop a vaccine for Chlamydia. The company has identified a surface adhesin protein that will undergo preclinial testing as a subunit vaccine. ...